Anticarcinogenic Agents

• 

  Subject Areas on Research

  • Analgesic medication use and risk of epithelial ovarian cancer in African American women. 
  • Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. 
  • Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. 
  • Breast cancer anxiety's associations with responses to a chemoprevention decision aid. 
  • Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. 
  • Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. 
  • Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 
  • Distinguishing effects on tumor multiplicity and growth rate in chemoprevention experiments. 
  • Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. 
  • Effect of neuronol on lifespan and development of spontaneous tumors in SAMP-1 mice with genetically accelerated aging. 
  • Effects of phenethyl isothiocyanate, a carcinogenesis inhibitor, on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats. 
  • Gene duplication in the diversification of secondary metabolism: tandem 2-oxoglutarate-dependent dioxygenases control glucosinolate biosynthesis in Arabidopsis. 
  • Inhibition of CYP1A1 enzyme activity in mouse hepatoma cell culture by soybean isoflavones. 
  • Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen. 
  • Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). 
  • Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer. 
  • Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. 
  • Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. 
  • Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. 
  • Resveratrol arrests the cell division cycle at S/G2 phase transition. 
  • Safety and efficacy of weekly oral oltipraz in chronic smokers. 
  • Strain-specific altered nicotine metabolism in 3,3'-diindolylmethane (DIM) exposed mice. 
  • Structure-activity relationships of arylalkyl isothiocyanates for the inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism and the modulation of xenobiotic-metabolizing enzymes in rats and mice. 
  • Tamoxifen reduces plasma homocysteine levels in healthy women. 
  • The epidemiology of tea consumption and colorectal cancer incidence. 
  • The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. 
  • The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. 
  • Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion. 
  • Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. 
  • Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.